Prof. Dirk Busch, Patricia Gräf and Veit Buchholz (Photo: Astrid Eckert / TUM)
Prof. Dirk Busch, Patricia Gräf and Veit Buchholz (Photo: Astrid Eckert / TUM)

A fundamental finding with implications for clinical cell therapyExperiments prove "stemness" of individual immune memory cells

Researchers in Germany and the U.S. have proven for the first time that specific individual cells of the immune system, termed central memory T cells, have all the essential characteristics of adult tissue stem cells. Such cells are capable of perpetuating themselves indefinitely as well as generating diverse offspring that can reconstitute "tissue" function. These findings indicate that it should be possible to fully restore specific immunity to pathogens in patients with a compromised immune system by substitution of small numbers of central memory T cells. The results, published in the journal Immunity, highlight the therapeutic promise of "stemness" in T cells.

The immune system has evolved to recognize and respond to threats to health, and to provide life-long memory that prevents recurrent disease. A detailed understanding of the mechanism underlying immunologic memory, however, has remained elusive. Since 2001, various lines of research have converged to support the hypothesis that the persistence of immune memory arises from a reservoir of immune cells with stem-cell-like potential. Until now, there was no conclusive evidence, largely because experiments could only be carried out on populations of cells. This first strict test of the stem cell hypothesis of immune memory was based on mapping the fates of individual T cells and their descendants over several generations.

That experimental capability was developed through a long-term collaboration, focused on clinical cell processing and purification, between researchers based in Munich and Seattle. Since 2009, the groups of Prof. Dirk Busch at the Technische Universität München (TUM) and Prof. Stanley Riddell at the Fred Hutchinson Cancer Research Center have combined their technological and clinical expertise under the auspices of the TUM Institute for Advanced Study. The University of Heidelberg, the University of Düsseldorf, the Helmholtz Center Munich, the German Cancer Research Center (DKFZ), and the National Center for Infection Research (DZIF) also contributed to the present study.

Homing in on the "stemness" of T cells

After generating an immune response in laboratory animals, TUM researchers Patricia Graef and Veit Buchholz separated complex "killer" T cell populations enlisted to fight the immediate or recurring infection. Within these cell populations, they then identified subgroups and proceeded with a series of single-cell adoptive transfer experiments, in which the aftermath of immune responses could be analyzed in detail. Here the ability to identify and characterize the descendants of individual T cells through several generations was crucial.

The researchers first established that a high potential for expansion and differentiation in a defined subpopulation, called "central memory T cells," does not depend exclusively on any special source such as bone marrow, lymph nodes, or spleen. This supported but did not yet prove the idea that certain central memory T cells are, effectively, adult stem cells. Further experiments, using and comparing both memory T cells and so-called naive T cells – that is, mature immune cells that have not yet encountered their antigen – enabled the scientists to home in on stem-cell-like characteristics and eliminate other possible explanations.

Step by step, the results strengthened the case that the persistence of immune memory depends on the "stemness" of the subpopulation of T cells termed central memory T cells: Individual central memory T cells proved to be "multipotent," meaning that they can generate diverse types of offspring to fight an infection and to remember the antagonist. Further, these individual T cells self-renew into secondary memory T cells that are, again, multipotent at the single-cell level. And finally, individual descendants of secondary memory T cells are capable of fully restoring the capacity for a normal immune response.

Insights with clinical potential

One implication is that future immune-based therapies for cancers and other diseases might get effective results from adoptive transfer of small numbers of individual T cells. "In principle, one individual T cell can be enough to transfer effective and long-lasting protective immunity for a defined pathogen or tumor antigen to a patient," says Prof. Dirk Busch, director of the Institute for Medicial Microbiology, Immunology and Hygiene at TUM. "Isn't that astonishing?"

"These results are extremely exciting and come at a time when immunotherapy is moving into the mainstream as a treatment for cancer and other diseases," says Prof. Stanley Riddell of the Fred Hutchinson Cancer Research Center and the University of Washington. "The results provide strong experimental support for the concept that the efficacy and durability of T cell immunotherapy for infections and cancer may be improved by utilizing specific T cell subsets."

This research was supported by the German Research Foundation (DFG) through SFB TR36 (TP-B10/13) and SFB 1054 (TP-B09); by the Initiative and Networking Fund of the Helmholtz Association within the Helmholtz Alliance on Immunotherapy of Cancer; by the Federal Ministry of Education and Research (BMBF) through the e:Bio program (T-Sys); and by the U.S. National Science Foundation under Grant No. NSF PHY11-25915.

Publication
"Serial transfer of single cell-derived immunocompetence reveals stemness of CD8+ central memory T cells," Patricia Graef, Veit R. Buchholz, Christian Stemberger, Michael Flossdorf, Lynette Henkel, Matthias Schiemann, Ingo Drexler, Thomas Höfer, Stanley R. Riddell, and Dirk H. Busch. Immunity, Vol. 41, Issue 1, July 17, 2014.
DOI: 10.1016/j.immuni.2014.05.018

Contact
Prof. Dr. Dirk H. Busch
Institute for Medical Microbiology, Immunology and Hygiene
Technische Universität München
Tel: +49 89 4140 4120
dirk.busch(at)tum.de
www.mikrobio.med.tu-muenchen.de

Corporate Communications Center

Technical University of Munich Patrick Regan
patrick.regan(at)tum.de

Article at tum.de

Research group leader Dr. Veit Buchholz (left) and first author Lorenz Mihatsch from the Institute for Medical Microbiology, Immunology and Hygiene.

How the immune system remembers viruses

For a person to acquire immunity to a disease, T cells must develop into memory cells after contact with the pathogen. Until now, the number of cells that do this was believed to depend above all on the magnitude of the...

T-cell lymphocytes with receptors for killing cancer cells in cancer immunotherapy.

The tricks of the immune system

More than half of the world's population is infected with the cytomegalovirus. The majority of people don't even notice the infection, since their immune systems keep the virus in check. Groups of T cells with a variety of...

Prof. Dr. Christian Peschel

A life's work for stem cell research

Today blood stem cells are frequently used in therapy to treat leukemia and lymphoma. But decades of research were necessary before the first successful applications in treatment. On January 21 in the series "Tech-Histories...

Prof. Dirk Busch und Prof. Michael Sattler. (Bild: A. Heddergott und A. Eckert / TUM)

Dirk Busch and Michael Sattler become members of Leopoldina

The German National Academy of Sciences Leopoldina has appointed a medical scientist and a chemist from the Technical University of Munich as new members: Prof. Dirk Busch, Professor of Medical Microbiology, Immunology and...

Ein Labortest

The needle in the haystack

New cancer therapies harness the immune system to fight tumors. One of the main principles behind these therapies is to find out precisely which molecules on cancer cells trigger an immune response. A team at the Technical...

Tumorzelle mit hervorgehobenen Proteinen in der Zellwand (FOTO: Bassermann/TUM)

Scientists discover mechanism of thalidomide

In the 1950s, thalidomide (Contergan) was prescribed as a sedative drug to pregnant women, resulting in a great number of infants with serious malformations. Up to now, the reasons for these disastrous birth defects have...

Auf der Abbildung ist eine Gewebezelle des Knochenmarks einer Maus zu sehen, die den Botenstoff CTGF (rot) absondert. Der Zellkern ist in blau angefärbt. (Bild: Rouzanna Istvanffy / TUM)

Blood stem cell self-renewal dependent on surroundings

Stem cells have two important capabilities: they can develop into a wide range of cell types and simultaneously renew themselves, creating fresh stem cells. Using a model of the blood forming (hematopoietic) system,...

Christoph Vahl, Erstautor der Studie, untersuchte die Tregs und die Rolle ihres T-Zell-Rezeptors. (Foto: C. Vahl / TUM)

T cell receptor ensures Treg functionality

Misdirected immune responses that target the body’s own tissue can result in human diseases. Regulatory T cells known as Tregs combat this effect by suppressing excessive immune responses and responses against our own...

Prof. Jürgen Ruland (rechts) erforscht mit seiner Arbeitsgruppe unter anderem die Entstehung und Bekämpfung von Lymphomen. (Bild: A. Heddergott / TUM)

Side effects of possible anti-cancer strategy discovered

The Malt1 protein is one of the most important control centers in human immune cells and a real all-rounder. Genetic defects in it can lead to the development of lymphatic cancer (lymphoma). A possible therapeutic approach...

Prof. Percy Knolle (rechts) erforscht mit seiner Arbeitsgruppe unter anderem die Regulation von Immunantworten in der Leber. (Bild: A. Heddergott / TUM)

Synthetic messenger boosts immune system

Specific immune cells, known as T lymphocytes, have to be activated so that the body can develop long-term protection against infections. Previously, it was believed that this process only took place in the lymph nodes and...

Weil die Arbeit mit Zellen hochreine Bedingungen erfordern, tragen die Mitarbeiter in den Reinräumen sterile Bekleidung. (Foto: M. Neuenhahn / TUM)

Promising T cell therapy

When patients have to undergo a bone marrow transplant, the procedure weakens their immune system. Viruses that are usually kept in check in a healthy immune system may then cause potentially fatal infections. Scientists...